PTC Therapeutics (PTCT) Competitors $61.09 +0.13 (+0.21%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$61.11 +0.02 (+0.03%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PTCT vs. VTRS, ASND, RDY, QGEN, BBIO, MRNA, ELAN, VRNA, ROIV, and RVMDShould you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. PTC Therapeutics vs. Its Competitors Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories Qiagen BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Revolution Medicines PTC Therapeutics (NASDAQ:PTCT) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk. Do analysts prefer PTCT or VTRS? PTC Therapeutics currently has a consensus price target of $69.00, suggesting a potential upside of 12.95%. Viatris has a consensus price target of $10.40, suggesting a potential upside of 4.42%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe PTC Therapeutics is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Does the media favor PTCT or VTRS? In the previous week, PTC Therapeutics had 16 more articles in the media than Viatris. MarketBeat recorded 19 mentions for PTC Therapeutics and 3 mentions for Viatris. PTC Therapeutics' average media sentiment score of 1.00 beat Viatris' score of 0.30 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, PTCT or VTRS? PTC Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Do institutionals & insiders hold more shares of PTCT or VTRS? 79.9% of Viatris shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is PTCT or VTRS more profitable? PTC Therapeutics has a net margin of 35.65% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% Viatris -24.57%16.54%7.06% Which has preferable valuation & earnings, PTCT or VTRS? PTC Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M6.02-$363.30M$6.978.76Viatris$14.12B0.82-$634.20M-$2.90-3.43 SummaryPTC Therapeutics beats Viatris on 12 of the 16 factors compared between the two stocks. Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTCT vs. The Competition Export to ExcelMetricPTC TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.84B$3.20B$5.86B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio8.7621.1774.8625.97Price / Sales6.02438.17517.12182.33Price / CashN/A46.6837.5660.44Price / Book-4.299.6112.156.29Net Income-$363.30M-$53.29M$3.29B$270.96M7 Day Performance6.69%0.13%0.73%3.87%1 Month Performance26.82%5.61%4.82%4.87%1 Year Performance79.73%10.49%60.58%26.12% PTC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTCTPTC Therapeutics3.668 of 5 stars$61.09+0.2%$69.00+12.9%+86.8%$4.84B$806.78M8.761,410News CoveragePositive NewsInsider TradeVTRSViatris1.4446 of 5 stars$10.55+1.3%$10.40-1.4%-15.2%$12.30B$14.12B-3.6432,000ASNDAscendis Pharma A/S3.2008 of 5 stars$194.27+0.2%$243.36+25.3%+71.8%$11.89B$393.54M-37.651,017Positive NewsRDYDr. Reddy's Laboratories2.477 of 5 stars$14.20-0.1%$16.95+19.4%-8.7%$11.85B$3.81B21.5127,811Positive NewsQGENQiagen4.4749 of 5 stars$46.53+0.9%$49.69+6.8%+2.2%$10.34B$2.04B27.495,765BBIOBridgeBio Pharma4.4494 of 5 stars$51.76-1.5%$62.18+20.1%+90.0%$9.89B$235.81M-12.66400Analyst ForecastMRNAModerna4.47 of 5 stars$24.09-1.6%$42.88+78.0%-66.3%$9.37B$3.06B-3.205,800Trending NewsELANElanco Animal Health2.6241 of 5 stars$18.38-0.4%$17.33-5.7%+28.7%$9.13B$4.48B21.379,000High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.1815 of 5 stars$105.91+0.0%$109.00+2.9%+254.9%$8.67B$221.67M-106.9830Positive NewsROIVRoivant Sciences3.1685 of 5 stars$11.93-0.1%$16.50+38.3%+16.2%$8.15B$29.05M-17.04860News CoveragePositive NewsOptions VolumeRVMDRevolution Medicines4.3009 of 5 stars$37.97-0.9%$69.92+84.2%+10.9%$7.10BN/A-8.44250Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies VTRS Alternatives ASND Alternatives RDY Alternatives QGEN Alternatives BBIO Alternatives MRNA Alternatives ELAN Alternatives VRNA Alternatives ROIV Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTCT) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
